Talphera Q4 net loss widens as operating expenses rise

Talphera

23/03/2026 12:39

Overview

US specialty pharma firm's Q4 net loss widened yr/yr, with negligible revenue

Operating expenses rose, driven by Niyad development and increased G&A costs

Company closed $4.1 mln financing tranche after reaching 50% enrollment in NEPHRO CRRT study

Outlook

Talphera expects 2026 cash operating expenses of $17 mln to $18 mln, up from $13 mln in 2025

Company expects NEPHRO CRRT study completion in 2026, with all sites now enrolling patients

Result Drivers

INCREASED R&D SPENDING - Higher R&D expenses, primarily related to Niyad development, drove up operating costs in Q4

CLINICAL STUDY PROGRESS - Costs rose as all 12 NEPHRO CRRT clinical study sites became active, supporting higher enrollment rates

Company press release: ID:nPn727sxMa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Net Income
Miss
-$3.77 mln
-$3.25 mln (1 Analyst)
Q4 Income From Operations
Beat
-$3.45 mln
-$3.77 mln (2 Analysts)
Q4 Net Income From Cont Ops
-$3.77 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Talphera Inc is $3.25, about 290.2% above its March 20 closing price of $0.83

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)